Head-To-Head Survey: Cortexyme (NASDAQ:CRTX) vs. ProKidney (NASDAQ:PROK)

ProKidney (NASDAQ:PROK) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Profitability

This table compares ProKidney and Cortexyme’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ProKidney	N/A	N/A	-10.24%
Cortexyme	N/A	-70.96%	-63.53%

Institutional and Insider Ownership

51.6% of ProKidney shares are held by institutional investors. Comparatively, 63.2% of Cortexyme shares are held by institutional investors. 41.5% of ProKidney shares are held by company insiders. Comparatively, 27.9% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

ProKidney has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Cortexyme has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500.

Earnings and Valuation

This table compares ProKidney and Cortexyme”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProKidney	N/A	N/A	-$35.47 million	($0.55)	-3.17
Cortexyme	N/A	N/A	-$89.94 million	($2.97)	-0.65

ProKidney is trading at a lower price-to-earnings ratio than Cortexyme, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for ProKidney and Cortexyme, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProKidney	0	3	2	0	2.40
Cortexyme	0	0	0	0	0.00

ProKidney presently has a consensus target price of $4.50, suggesting a potential upside of 157.88%. Given ProKidney’s stronger consensus rating and higher possible upside, equities research analysts clearly believe ProKidney is more favorable than Cortexyme.

Summary

ProKidney beats Cortexyme on 8 of the 11 factors compared between the two stocks.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

About Cortexyme

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.